Metsera, Inc. (MTSR) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 New York City, NY, 미국. 현재 CEO는 Christopher Whitten Bernard.
MTSR 을(를) 보유 IPO 날짜 2025-01-31, 93 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $7.43B.
Metsera, Inc. is a clinical-stage biotechnology company developing injectable and oral hormone analog peptides designed to treat obesity, overweight, and related metabolic disorders. The company's pipeline includes MET-097i and MET-233i for obesity and overweight management, as well as MET-002, MET-224o, MET-067i, and MET-034i for treating conditions including diabetes and obesity. Founded in 2022 and based in New York, Metsera is advancing nutrient-stimulated therapeutic candidates toward clinical development.
